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Clinical indicators to identify neuropathic
pain in low back related leg pain: a
modified Delphi study
Jai Mistry1,2, Deborah Falla2, Tim Noblet1,2, Nicola R. Heneghan2 and Alison Rushton2*
Abstract
Background: Neuropathic pain (NP) is common in patients presenting with low back related leg pain. Accurate
diagnosis of NP is fundamental to ensure appropriate intervention. In the absence of a clear gold standard, expert
opinion provides a useful methodology to progress research and clinical practice. The aim of this study was to
achieve expert consensus on a list of clinical indicators to identify NP in low back related leg pain.
Methods: A modified Delphi method consisting of three rounds was designed in accordance with the Conducting
and Reporting Delphi Studies recommendations. Recruitment involved contacting experts directly and through
expressions of interest on social media. Experts were identified using pre-defined eligibility criteria. Priori consensus
criteria were defined for each round through descriptive statistics. Following completion of round 3 a list of clinical
indicators that achieved consensus were generated.
Results: Thirty-eight participants were recruited across 11 countries. Thirty-five participants completed round 1
(92.1%), 32 (84.2%) round 2 and 30 (78.9%) round 3. Round 1 identified consensus (Kendall’s W coefficient of
concordance 0.456; p < 0.001) for 10 clinical indicators out of the original 14, and 9 additional indicators were
added to round 2 following content analysis of qualitative data. Round 2 identified consensus (Kendall’s W
coefficient of concordance 0.749; p < 0.001) for 10 clinical indicators out of 19, and 1 additional indicator was added
to round 3. Round 3 identified consensus for 8 indicators (Kendall’s W coefficient of concordance 0.648; p < 0.001).
Following completion of the third round, an expert derived consensus list of 8 items was generated. Two
indicators; pain variously described a burning, electric shock like and/or shooting into leg and pain in association
with other neurological symptoms (e.g. pins and needles, numbness, weakness), were found to have complete
agreement amongst expert participants.
Conclusions: Good agreement was found for the consensus derived list of 8 clinical indicators to identify NP in low
back related leg pain. This list of indicators provide some indication of the criteria upon which clinicians can identify a
NP component to low back related leg pain; further research is needed for stronger recommendations to be made.
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Background
Neuropathic pain (NP) represents a substantial bur-
den globally, to the individual and the wider economy
[1]. According to the International Association for the
Study of Pain (IASP), NP is defined as “pain arising
from a disease or lesion of the somatosensory nervous
system” [2]. Global NP prevalence reports are esti-
mated to be between 6.9–10% [3]. Chronic low back
pain is the most common type of NP disorder [4],
presenting as low back related leg pain; often referred
to as sciatica [5]. In comparison to low back pain
alone, low back related leg pain is associated with
substantially greater pain levels and poorer quality of
life [5]. Furthermore, individuals with low back re-
lated leg pain with NP have been found to have a
poorer prognosis compared to those with low back
related leg pain without NP [5].
Low back related leg pain manifests as numerous
different clinical presentations presenting as a highly
heterogenous phenomenon. NP is a common pain
mechanism involved in low back related leg pain,
however it is not exclusive to, or a requirement of
low back related leg pain [6]. The pathophysiology
that governs NP in low back related leg pain is likely
due to multifaceted processes including mechanical
[7], ischemic [8] and neuroinflammatory [9] compo-
nents. The combination of these components dictates
the neurophysiological changes that occur, resulting
in a presentation such as lumbar radicular pain.
These patho-mechanics differ to those that would
underlie a primarily nociceptive expression of low
back related leg pain, such as that seen in somatic/
referred pain presentations [10]. It is clear that pain
mechanisms coexist in low back related leg pain [11]
however in order for management to be effective, an
understanding of the presence of NP is essential, as
this knowledge will help to direct treatment [5]. This
is highlighted by the NICE guidelines for low back
pain with sciatica [12] which recommend pharma-
ceutical intervention to align with the NICE guide-
lines for NP [13], this differs to the
recommendations made for low back pain alone.
Furthermore, it is advocated that pain medication
targeted at a pain mechanism over a specific path-
ology is found to be more effective [14].
Guidelines governing NP (European Federation of
Neurological Societies, National Institute for Health
and Care Excellence, Canadian Pain Society) uni-
formly recommend management that is specific to
pharmaceutical intervention [15]. Therefore, accurate
diagnosis of NP in low back related leg pain is essen-
tial to ensure effective management. Despite the vast
interest surrounding NP there is no accepted gold
standard for diagnosing NP in low back related leg
pain [16]. Our recent systematic review investigated
the diagnostic utility of clinical indicators to identify
NP in low back related leg pain [17], finding a lack
of uniformity across included studies for reference
standards and terminology relating to NP in low back
related leg pain. The review’s conclusion was a need
for consensus regarding a reference standard to en-
able evaluation of diagnostic utility of clinical
indicators for NP in low back related leg pain. The
NP Special Interest Group (NeuSPIG) published a
grading system for NP in 2008 [2] which was then re-
vised in 2016 [18]. The grading system indicates the
level of certainty (possible, probable, and definite) for
which the presence of NP can be determined. A cen-
tral component for all levels of certainty requires
“neuroanatomically plausible” patterns of pain/sensory
symptoms, however there is evidence to refute classic
neuroanatomic patterns of symptom distribution for
example, for entrapment neuropathies [19]. Further-
more, to achieve a ‘definite’ level of certainty the use
of diagnostic tests is recommended; including the use
of imaging, however it is well understood that lumbar
spine imaging can highlight structural abnormalities
that do not necessarily correlate with symptom pres-
entation [20], and therefore this grading system must
be used with caution.
Smart et al. [21] generated a list of fourteen clinical
indicators to identify NP in musculoskeletal pain, in a
Delphi survey of experts. This research was aimed at
identifying NP in musculoskeletal pain and therefore
these indicators may not be specific to low back re-
lated leg pain. The clinical classification accuracy of
these indicators were investigated in low back pain
patients with and without leg pain [22], finding that a
cluster of two symptoms and one sign demonstrated
a high level of classification accuracy. However, this
study has been highlighted as being at risk of bias,
due to clinicians not being blinded to the results of
the reference standard before conducting the index
test, therefore the results must be observed with cau-
tion [17]. Smart et al’s original list of clinical indica-
tors to identify NP in musculoskeletal pain serves as
a useful starting point, however an update of this list
is required. Firstly, the list of clinical indicators must
be specific to NP in low back related leg pain not to
musculoskeletal pain. Secondly, elements of Smart
et al’s list have been disputed due to evidence that
has since been published, as highlighted in this
study’s protocol [23]. Therefore, an updated version
of Smart et al’s Delphi is needed in order to devise a
list of clinical indicators specific to identifying NP in
low back related leg pain. In the absence of a gold
standard, an updated expert derived consensus list will
help to address the gap in the literature. Expert opinion
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provides an effective means to address areas of clinical un-
certainty through consensus [24].
Aim
To achieve expert consensus on a list of clinical indica-
tors to identify NP in low back related leg pain.
Methods
Design
A modified Delphi study was conducted, informed
by a pre-defined and published protocol [23] and is
reported in line with the Conducting and Reporting
Delphi Studies (CREDES) recommendations to en-
sure rigour. RedCap (https://www.project-redcap.org)
was used as a platform to construct and distribute
three rounds of surveys to participants. Participants
were given 2 weeks to complete each round and 1
week was allocated per round for data analysis. Re-
sults from rounds 1 and 2 informed the construction
of the subsequent round survey. Non-responders
were sent 3 reminders per round at equally distrib-
uted intervals. Agreement was defined according to
pre-defined consensus criteria per round using de-
scriptive statistics. At the end of round 3, participants
ranked the patient history and clinical examination indica-
tors in terms of importance. Clinical indicators were
retained for subsequent rounds if consensus was achieved
and were removed if consensus was not achieved. Feed-
back was given to participants for rounds 2 and 3 regard-
ing the previous round's results. The clinical indicators
generated following round 3 were collated to create the
final list of clinical indicators to identify NP in low back
related leg pain. Figure 1 depicts the procedure in stages
of the modified Delphi study.
Steering committee
The steering committee made collective decisions regard-
ing methodology, data analysis and quality assurance. The
steering committee was comprised of the 5 authors of this
study. The lead author (JM) and co-author (TN) were stu-
dents (MRes and PhD) at the University of Birmingham.
The remaining 3 members of the steering committee were
comprised of senior academics at the University of
Birmingham (AR, DF, NH), who were also were acting in
a supervisory capacity for the lead author (JM).
Participants
In line with the CREDES recommendations, experts
were defined according to pre-defined eligibility cri-
teria. The eligibility criteria were informed by previous
similar studies [25, 26], and agreed upon by the steering
committee.
Eligibility criteria (≥ 1 criterion required for inclusion):
 ≥ 2 peer-reviewed publications in the field of NP in
low back related leg pain [25] or
 ≥ 10 years experience working in a pain/
musculoskeletal outpatient service
Expert participants were sought globally and from
a variety of different professional backgrounds
(physiotherapy, medicine, academia and other health-
care professional). An a priori minimum number of
participants was defined at 30, as agreed by the
steering committee; and based upon previous pub-
lished research [27]. An upper limit for participant
numbers was not defined.
Recruitment
The recruitment period duration was 6 weeks. A snow-
balling strategy was adopted by the 2 recruiting authors
(JM, TN), contacting experts through:
 Emailing authors of published systematic reviews
relating to NP in low back related leg pain
 Posting social media expressions of interest
Experts contacted were also requested to recommend
peers who satisfied the eligibility criteria. Participation was
confirmed following receipt of a signed consent form,
conflict of interest form and participant information form.
Procedure
A pilot was conducted prior to commencement of the
study. Eight students with musculoskeletal expertise
(MRes/MSc) were invited to complete the round 1
survey over a 1-week period and asked to feedback any
points to help improve the usability of the survey. Feed-
back was collated and no modifications were indicated.
Round 1
The survey for round 1 was constructed in RedCap
using a list of pre-defined criteria (see Fig. 2) [21].
Smart et al’s list of clinical indicators were used as
the initial indicators in Round 1 of this study. This
list was utilised as it consists of subjective and ob-
jective indicators which can be easily translated into
clinical practise. Furthermore, the list has been gen-
erated through a similar designed study and there-
fore easily compared to the current study. Specific
screening tools were not used as there is no consen-
sus regarding superiority of one over the other, and
furthermore none are validated in identifying NP in
low back related leg pain [17]. The 2016 NeuPSIG
recommendations for diagnosing NP were not used
in this study. Imaging is a requirement for certain
criteria within these recommendations, and thus not
clinically applicable to all [18].
Mistry et al. BMC Musculoskeletal Disorders          (2020) 21:601 Page 3 of 15
Distribution of all surveys were administered
through RedCap and participants were given 2 weeks
to complete each survey. Participants who did not re-
spond were removed from this study. Consensus was
assessed through analysing descriptive statistics
against pre-defined criteria for consensus. Content
analysis was used to analyse data from the free text
boxes; themes were identified which helped to inform
the construction of the round 2 survey. Results of the
descriptive statistics and content analysis were fed
back to the steering committee and discussed before
constructing the round 2 survey. Feedback regarding
round 1 was sent to all participants as part of the
round 2 survey.
Round 2
Data analysis and steering committee feedback/discus-
sion were completed as per round 1 and the round 3
survey was constructed. Feedback regarding round 2
Fig. 1 Stages of Modified Delphi study
Mistry et al. BMC Musculoskeletal Disorders          (2020) 21:601 Page 4 of 15
was sent to all participants as part of the round 3
survey, to those who completed round 2.
Round 3
Data analysis and steering committee feedback/discus-
sion were completed as per rounds 1 and 2. An
additional component to the round 3 survey was im-
plemented; at the end of the survey all the indicators
were divided into patient history and clinical examin-
ation sections and participants were invited to rank
them in terms of their importance. On completion of
Fig. 2 Smart’s original consensus criteria [21]
Table 1 Priori consensus criteria per round
Round 1 Median value of participants Likert scale data ≥ 3
Percentage of agreement 50%
Round 2 Median value of participants Likert scale data ≥ 3.5
IQR value of participants Likert scale data ≤ 2
Percentage of agreement 60%
Round 3 Median value of participants Likert scale data ≥ 4
IQR value of participants Likert scale data ≤ 1
Percentage of agreement 70%
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round 3, and following analysis a list of indicators
that achieved consensus were generated.
Data management and analysis
All data analyses were initially completed by the lead
investigator (JM) and the second reviewer (TN). De-
scriptive data were inputted into SPSS (Version 25.0.
Armonk, NY: IBM Corp.) for statistical analysis.
Qualitative data were collated in a Word document
for analysis.
A priori consensus criteria were set based on Likert
scale scores (5 = Strongly agree, 4 = Agree, 3 = No
opinion, 2 = Disagree, 1 = Strongly disagree) for each
round using descriptive statistics consisting of median,
inter quartile range (IQR) and percentage of agree-
ment, in line with previously published research
(Table 1) [25]. Kendall’s W coefficient of concordance
(statistical significance set at p < 0.05) was used for
each round to assess overall agreement between par-
ticipants and, was also used to assess agreement with
ranking in round 3. Kendall’s W coefficient of con-
cordance agreement figures were interpreted as poor
agreement ≤ 0.20, fair agreement 0.21 to 0.40, moder-
ate agreement 0.41 to 0.60, good agreement 0.61 to
0.80, and very good agreement 0.81 to 1.00 [28].
Results
Participants
Thirty-eight participants were recruited across 11
countries, their experience working with NP in low
back related leg pain ranged from 10 to 35 years and
they comprised primarily of physiotherapists and
researchers/academics. Participants who were resident
in the United Kingdom formed the majority of the
study cohort (71%). Most participants were physio-
therapists (68%), one was an osteopath and another
was a neuroscientist. The remaining participants were
working in academia (29%). The most common high-
est academic qualification amongst participants was a
MSc (55%) followed by a PhD (37%). The most com-
mon time period to be working within the relevant
field was 10–15 years (74%). Of the included partici-
pants, 26% had ≥ 2 peer reviewed journals published
relating to NP in low back related leg pain. See
Table 2 for participant characteristics.
Round 1
Thirty-five participants completed round 1 (92.1%
response rate), 3 participants did not complete the survey.
Consensus was achieved with Kendall’s W coefficient of
concordance 0.456 (p < 0.001), for 10 clinical indicators
out of the original 14 (Table 3). Four indicators there-
fore did not achieve consensus (Table 3).
Table 2 Characteristics of participants
Characteristics of expert participants Total number
Gender
Male n = 24
Female n = 14
Age
30–39 n = 8
40–49 n = 21
50–59 n = 8
≥ 60 n = 1
Occupation
Physiotherapist n = 12
Extended scope Physiotherapist n = 9
Consultant Physiotherapist n = 4
Lecturer n = 5
Research fellow n = 1
Professor n = 3
PhD student n = 2
Neuroscientist n = 1
Osteopath n = 1
Country of origin
UK n = 20
Ireland n = 2
Australia n = 6
India n = 2
Switzerland n = 2
Norway n = 1
Netherlands n = 1
USA n = 1
Italy n = 1
South Africa n = 1
Greece n = 1
Highest academic qualification
BSc n = 1
PGDip n = 2
MSc n = 21
MRes n = 1
PhD n = 13
Time period working with NP
10–15 years n = 27
16–20 years n = 3
> 20 years n = 8
Peer review journal > 2
0 n = 28
2–5 n = 4
6–10 n = 0
> 10 n = 6
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Following content analysis of round 1 data 4 themes
were identified.
Pain descriptors need to be split into separate indicators
“............too many options in this sentence. Whilst I
agree with shooting and electric, many patients de-
scribe non-neuropathic low back pain as aching, burn-
ing, sharp, and sometimes shooting” (Participant 12)
“some of these descriptors I would associated with
neuropathic pain but not all of them” (Participant 10)
“ … …… … aching certainly not neuropathic, so this
question is difficult to answer, for burning, shooting,
electric shock, I would strongly agree” (Participant 3)
Latency of pain following aggravating factor
“can have a latency affect - which needs to be
considered” (Participant 2)
“Latency of pain - nerve pain will often manifest the
day after the aggravating activity” (Participant 26)
Positive small fibre testing
“one could also test the small fibres, as NDTs are
not enough in order to assess probably a UNT or
SLR properly” (Participant 33)
“need to continue to develop clinically feasible
methods for assessing function of smaller diameter
afferent fibers as part of sensory examination”
(Participant 22)
Indicators not exclusive to NP
“Agree that these terms would be used to describe
nerve root related leg pain, but not exclusively”
(Participant 9)
“I think this is a multifactorial and multi
symptomatic problem. It is an overall picture
involving a number of points made above but not
exclusively all” (Participant 23)
Following content analysis nine additional indicators
were included in the round 2 survey (Table 4). At the
Table 3 Round 1 descriptive statistics
Round 1 criteria for consensus:
✓ Median value of participants Likert scale data ≥ 3
✓ Percentage of agreement 50% (Wiangkham et al., 2016 [25])




Pain variously described as burning, shooting, sharp, aching or electric-shock-like 4 85.7% Y
History of nerve injury, pathology or mechanical compromise 4 77.2% Y
Pain in association with other neurological symptoms (e.g. pins and needles,
numbness, weakness)
4 77.2% Y
Pain referred in a dermatomal or cutaneous distribution 3 48% N
Less responsive to simple analgesia/NSAIDS and/or more responsive to
anti-epileptic (e.g. Neurontin, Lyrica)/anti-depression (e.g. Amitriptyline) medication
3 39% N
Pain of high severity and irritability (i.e. easily provoked, taking longer to settle) 4 54.3% Y
Mechanical pattern to aggravating and easing factors involving activities/postures
associated with movements, loading or compression of neural tissue
3 42.9% N
Pain in association with other dysesthesias (e.g. crawling, electrical, heaviness) 4 68.6% Y
Reports of spontaneous pain (i.e. stimulus independent) and/or paroxysmal pain
(i.e. sudden recurrences and intensification of pain)
4 51.4% Y
Pain/symptom provocation with mechanical/movement tests (e.g. Active/Passive,
Neurodynamic, i.e. SLR, Brachial plexus tension test) that move/load/compress
neural tissue
4 65.7% Y
Pain/symptom provocation on palpation of relevant neural tissues 4 51.4% Y
Positive neurological signs (including altered reflexes, sensation and muscle power
in dermatomal/myotomal or cutaneous nerve distribution)
4 63.8% Y
Antalgic posturing of the affected limb/body part 2 37.1% N
Positive findings of hyperalgesia (primary or secondary) and/or allodynia and/or
hyperpathia within the distribution of pain
4 57.2% Y
Mistry et al. BMC Musculoskeletal Disorders          (2020) 21:601 Page 7 of 15
end of each indicator “increases your index of suspicion
that there is a NP component to low back related leg
pain” was added.
Round 2
Thirty-two participants completed round 2 (84.2% response
rate), 3 participants did not complete the survey. Consensus
was achieved with Kendall’s W coefficient of concordance
0.749 (p < 0.001) for 12 clinical indicators out of 19 (Table 4).
Seven indicators did not achieve consensus (Table 4).
Following content analysis of round 2 data, 2
themes were identified.
History of nerve lesion or disease of somatosensory nervous
system is difficult to identify/define
“this is of course the IASP definition of NP, that it
has to be associated with a lesion or disease of
SSNS, tricky bit is that often in clinics it is not so
straightforward to demonstrate the lesion/disease”
(Participant 29)
“mechanical compromise is difficult to define and
will be interpreted differently by various profes-
sions / therapists” (Participant 10)
“I'm not sure exactly what mechanical compromise
means here” (Participant 31)
As well as a history of nerve injury, pathology or
mechanical compromise other factors can contribute to the
development of NP in low back related leg pain
“metabolic changes / diabetic or autoimmune dis-
eases” (Participant 8)
“recent or past chemotherapeutic drugs prescription”
(Participant 11)
Table 4 Round 2 descriptive statistics
Round 2 criteria for consensus include:
✓ Median value of participants Likert scale data ≥ 3.5
✓ IQR value of participants Likert scale data ≤ 2
✓ Percentage of agreement 60% (Wiangkham et al., 2016 [25])




Pain described as burning 4 1 90.9% Y
Pain described as shooting 4 1 73.8% Y
Pain described as sharp 3 1 18.2% N
Pain described as aching 2 2 12.1% N
Pain described as electric-shock-like/electrical 4 1 93.9% Y
Pain described as cramping 3 2 30.3% N
Pain described as crawling 4 1 66.7% Y
Pain described as heaviness 3 2 33.3% N
History of nerve injury, pathology or mechanical compromise 5 1 90.9% Y
Pain in association with other neurological symptoms (e.g. pins and needles,
numbness, weakness)
5 1 96.9% Y
Pain of high severity and irritability (i.e. easily provoked, taking longer to settle) 4 1 72.8% Y
Reports of spontaneous pain (i.e. stimulus independent) and/or paroxysmal
pain (i.e. sudden recurrences and intensification of pain)
4 2 72.7% Y
Pain/symptom provocation with mechanical/movement tests (e.g. Active/
Passive, Neurodynamic, i.e. SLR, Brachial plexus tension test, prone knee bend)
4 1 67.9% Y
Pain/symptom provocation on palpation of relevant neural tissues 4 1 57.6% N
Positive neurological signs (including altered reflexes, sensation and muscle
power in dermatomal/myotomal or cutaneous nerve distribution)
5 1 94% Y
Positive findings of hyperalgesia (primary or secondary) 3 2 42.4% N
Allodynia and/or hyperpathia within the distribution of pain 4 2 66.7% Y
Latent pain response to aggravating factor 4 1 51.5% N
Positive small fibre nerve testing findings (Hot/cold etc....) 4 1 84.8% Y
SLR Straight leg raise. Additional indicators indicated in bold
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“immune compromise e.g. HIV” (Participant 19)
Following content analysis one additional indicator was
included for round 3 (Table 5).
Furthermore, the pain descriptors that achieved consen-
sus were combined into one indicator.
Also, the indicator “History of nerve injury, pathology
or mechanical compromise increases your index of sus-
picion that there is a NP component to low back related
leg pain” was modified to further specify the location of
compromise.
Round 3
Thirty participants completed round 3 (78.9% response
rate), two participants did not complete the survey. Con-
sensus was achieved for 8 indicators, Kendall’s W coeffi-
cient of concordance 0.648 (p < 0.001) (Table 5). Three
indicators did not achieve consensus (Table 5).
Following content analysis 3 themes were identified.
Other factors such as metabolic, hormonal etc. …
contributors are too general and not specific enough when
identifying NP in low back related leg pain
“Will be used in the clinical reasoning process, but
need other descriptors or indicators. In isolation,
not indicative of neuropathic pain” (Participant 3)
“Although diabetes and radiotherapy can result in
NP, this has is not low back-related”, “I suppose it
may make you consider that their nervous system is
more vulnerable, but whether it means that they
have a NP component to their low back pain is
unclear” (Participant 11)
High severity and irritability not specific enough to identify
NP in low back related leg pain
“it can be part of the picture of neuropathic pain,
but not totally discriminatory” (Participant 6)
Table 5 Round 3 descriptive statistics
Round 3 criteria for consensus include:
✓ Median value of participants Likert scale data ≥ 4
✓ IQR value of participants Likert scale data ≤ 1
✓ Percentage of agreement 70% (Wiangkham et al., 2016 [25])










Pain variously described as burning, electric shock like and/or
shooting into leg
5 1 100 Yes 2
Pain described as crawling or another unpleasant abnormal sensation
(as a common example of dysesthesia)
4 1 90.3 Yes 4
History of nerve injury, pathology or mechanical compromise at the
region of the nerve root/or other nervous tissue around the lumbar
spine that can refer into the leg
5 1 96.7% Yes 3
In a patient with low back related leg pain does the pre-existing
knowledge of metabolic (e.g. diabetes, vitamin deficiencies),
hormonal (e.g. thyroid), genetic (e.g. channelopathies),
pharmacological (antimetabolities), chemical
(e.g. chemotherapy) conditions
3 1 48.5% No 7
Pain in association with other neurological symptoms (e.g. pins and
needles, numbness, weakness)
5 1 100% Yes 1
Pain of high severity and irritability (i.e. easily provoked, taking longer
to settle)
4 2 64.5% No 6
Reports of spontaneous pain (i.e. stimulus independent) and/or
paroxysmal pain (i.e. sudden recurrences and intensification of pain)
4 1 71.1% Yes 5
Pain/symptom provocation with mechanical/movement tests (e.g.
Active/Passive, Neurodynamic, i.e. SLR, Brachial plexus tension test)
4 1 67.8% No 3
Positive neurological signs (including altered reflexes, sensation and
muscle power in dermatomal/myotomal or cutaneous nerve
distribution)
5 1 90.4% Yes 1
Allodynia and/or hyperpathia within the distribution of pain 4 1 74.2% Yes 4
A loss of function of small fibre testing 4 1 77.4% Yes 2
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“ … …… … these components are too non-specific
to even increase my index of suspicion of a neuro-
pathic component to low back-related leg pain.
While nerve-related problems can often be higher
on the severity and irritability scales, non-neural/
nociceptive problems can also be high on these
scales” (Participant 28)
Neurodynamic testing
“I would not consider a positive lower limb
neurodynamic tests to be relevant here. As
previously mentioned, a negative SLR/Slump tests
etc. does not mean that NP is not present esp. In
the presence of nerve function loss, and its presence
does not tell you for sure that there is NP component
as we know many people with positive. Neurodynamic
tests do not have NP. So whilst I agree that its
presence may raise my suspicion, it is other factors as
well that would confirm its presence” (Participant 14)
“ …………heightened nerve mechanosensitivity is
NOT the same as neuropathic pain. Quite often
heightened nerve mechanosensitivity is associated
with nociceptive pain. This is a huge fallacy in
contemporary Physiotherapy, and often
misinterpreted...see many studies which show that
neurodynamic tests can be negative in patients with
properly diagnosed nerve lesions (so by your (IASP)
definition have neuropathic pain...)” (Participant 15)
Following completion of the third round, an expert de-
rived consensus list of 8 items was generated. See Table 6
for the list of clinical indicators.
Consensus on ranking
Rankings of clinical indicators were split into patient
history (Table 7) and clinical examination indicators
(Table 8). The two patient history indicators ranked as
the most important were “Pain in association with other
neurological symptoms (e.g. pins and needles, numbness,
weakness)” and “Pain variously described as burning,
electric shock like and/or shooting into leg increases
your index of suspicion of a NP component to low back
related leg pain.” The clinical examination indicator
ranked as the most important was “Positive neurological
signs (including altered reflexes, sensation and muscle
power in dermatomal/myotomal or cutaneous nerve
distribution).” Ranking order correlated with percentage
of agreement for all clinical indicators.
Agreement was assessed using Kendall’s W coefficient
of concordance. For patient history indicators alone,
agreement was 0.390 (fair agreement). For clinical exam-
ination indicators alone agreement was 0.204 (fair
Table 6 List of expert derived indicators to identify NP in low
back related leg pain
Pain variously described as burning, electric shock like and/or
shooting into leg (percentage of agreement 100%)
Pain described as crawling or another unpleasant abnormal
sensation (as a common example of dysesthesia) (percentage of
agreement 90.3%)
History of nerve injury, pathology or mechanical compromise at
the region of the nerve root/or other nervous tissue around the
lumbar spine that can refer into the leg (percentage of agreement
96.7%)
Pain in association with other neurological symptoms (e.g. pins
and needles, numbness and weakness) (percentage of agreement
100%)
Reports of spontaneous pain (i.e. stimulus independent) and/or
paroxysmal pain (i.e. sudden recurrences and intensification of
pain) (percentage of agreement 71%)
Positive neurological signs (including altered reflexes, sensation
and muscle power in dermatomal/myotomal or cutaneous nerve
distribution) (percentage of agreement 90.4%)
Allodynia and/or hyperpathia within the distribution of pain
(percentage of agreement 74.2%)
Loss of function of small fibre nerve testing (percentage of
agreement 77.4%)
Table 7 Ranking of patient history examination clinical
indicators that achieved consensus
1) Pain in association with other neurological symptoms (e.g. pins and
needles, numbness, weakness) increases your index of suspicion that
there is a NP component to low back related leg pain
2) Pain variously described as burning, electric shock like and/or
shooting into leg increases your index of suspicion of a NP
component to low back related leg pain.
3) History of nerve injury, pathology or mechanical compromise at the
region of the nerve root/or other nervous tissue around the lumbar
spine that can refer into the leg increases your index of suspicion of
a NP component to low back related leg pain.
4) Pain described as crawling or another unpleasant abnormal
sensation (as a common example of dysesthesia) increases your
index of suspicion of a NP component to low back related leg pain.
5) Reports of spontaneous pain (i.e. stimulus independent) and/or
paroxysmal pain (i.e. sudden recurrences and intensification of pain)
increases your index of suspicion that there is a NP component to
low back related leg pain
Ranking of importance: 1 = highest important, 5 = least important
Table 8 Ranking for clinical examination clinical indicators that
achieved consensus
1) Positive neurological signs (including altered reflexes, sensation and
muscle power in dermatomal/myotomal or cutaneous nerve
distribution) increases your index of suspicion that there is a NP
component to low back related leg pain
2) A loss of function of small fibre testing increases your index of
suspicion that there is a NP component to low back related leg pain
3) Allodynia and/or hyperpathia within the distribution of pain
increases your index of suspicion that there is a NP component to
low back related leg pain
Ranking of importance: 1 = highest important, 3 = least important
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agreement). Combining both patient history and clinical
examination indicators ranking results together agree-
ment was 0.431 (moderate agreement).
Discussion
This is the first study to derive an expert consensus list
of clinical indicators of possible NP specifically in pa-
tients with low back related leg pain. Over the 3 rounds
the overall response rate was 78.9% which is above the
recommended acceptable response rate for Delphi stud-
ies [29]. The outcome of this study is an expert derived
list of clinical indicators to identify possible NP in low
back related leg pain, with pragmatic implications for
both clinical practice and contemporary research once
further research is conducted to support this list of clin-
ical indicators.
The findings of this study identify complete agreement
(100%) for the use of pain descriptors and high agree-
ment (90.3%) for the use of dysesthesia descriptors for
identifying NP in low back related leg pain. The use of
pain descriptors and descriptors of dysesthesia are
commonly used in NP screening tools; such as the Leeds
Assessment of Neuropathic Symptoms and Signs (LANS
S) [30], PainDETECT [31] and the StEP tool [32].
Despite being a key feature of many screening tools, evi-
dence supporting the use of pain/dysesthesia descriptors
in identifying NP in low back related leg pain is limited
[17]. There is moderate level evidence to support the use
of the StEP tool, which encompasses the aforementioned
descriptors, in diagnosing lumbar radicular pain, demon-
strating high sensitivity (92%) and specificity (97%)
values [17]. However, the StEP tool also includes
numerous other patient history and clinical examination
components and thus the diagnostic accuracy of the
descriptors alone remain unclear. A difficulty associated
with use of specific pain/dysesthesia descriptors lies in
linguistic/cultural differences, which was highlighted in
the qualitative data from participants in this study.
When interpreting pain descriptors, in different lan-
guages or in the same language but in a different coun-
try, the descriptors may not always depict the culture’s
orientation and consequently the meaning may become
contaminated [33]. High levels of agreement in this
study support the use of pain descriptors and descriptors
of dysesthesia in identifying NP in low back related leg
pain. Further research is needed in order to assess the
diagnostic utility of these descriptors to enable stronger
recommendations to be made regarding their use.
History of nerve injury, pathology or mechanical com-
promise was a clinical indicator which remained from
Smart et al’s [21] original list, demonstrating high agree-
ment (96.7%). This indicator has been demonstrated to
have high sensitivity (86.3%) and specificity (96%) diag-
nosing peripheral NP in low back pain, with or without
leg pain, when used as part of a cluster of 3 clinical indi-
cators [22]. However, a low level of evidence supports
this cluster of clinical indicators when assessed using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) [17]. A degree of ambiguity,
highlighted by participants in this study, surrounds the
extent to which the nerve needs to be compromised to
be neuropathic and how this is identified in the absence
of obvious trauma. Heightened nerve mechanosensitivity
is considered a primarily nociceptive driven phenomenon,
in which nociceptors in the nervi nevorum are activated
as a consequence of the nerve itself being compromised
[19]. Despite being considered primarily nociceptive,
heightened nerve mechanosensitivity could be interpreted
as satisfying the indicator provided above. Through
the Delphi study this indicator was modified to
specify the region and structures involved. A high
level of agreement amongst participants supports the
use of this indicator. Research to investigate the
diagnostic utility of this indicator in isolation is
needed as well as clarity regarding what constitutes
nerve compromise.
Pain in association with other neurological symptoms
(e.g. pins and needles, numbness, weakness) and positive
neurological signs (including altered reflexes, sensation
and muscle power in dermatomal/myotomal or cutane-
ous nerve distribution) both demonstrated high agree-
ment (100 and 90.4% respectively) and were ranked as
the most important patient history and clinical examin-
ation indicators respectively (moderate agreement
Kendalls coefficient 0.431). Importantly these indicators
were highlighted to increase the index of suspicion of
NP in low back related leg pain but it was widely
acknowledged amongst participants that positive neuro-
logical findings can occur without NP and vice versa.
Evidence surrounding positive neurological symptoms/
findings in NP pertains largely to sensory findings [34],
with reflex and motor loss suggestive of radiculopathy,
which does not necessitate NP [35]. This is further sup-
ported by two systematic reviews investigating subjective
and objective indicators to identify peripheral NP [22]
and lumbosacral nerve root compression [36] respect-
ively, clusters of signs and symptoms were generated in
which motor/reflex loss were not featured but a com-
mon finding in both studies was sensory symptoms in a
dermatomal distribution. Interestingly in this study a
clinical indicator removed after round 1 was “Pain
referred in a dermatomal or cutaneous distribution.”
Our recent systematic review found that literature
surrounding the diagnostic utility of neurological signs
and symptoms in identifying NP in low back related leg
pain is sparse, with studies investigating these indicators
reporting them in clusters, not in isolation [17]. The
high level of agreement amongst participants, as well as
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being ranked the highest patient history and clinical
examination indicators, supports the use of both these
indicators in identifying NP in low back related leg pain.
However further research is needed to investigate the
diagnostic utility of neurological symptoms and signs,
and which of these symptoms and signs are relevant in
identifying NP in low back related leg pain.
Loss of function of small fibres achieved consensus in
this study, demonstrating moderate levels of agreement
(77.4%). Through the Delphi process, this was distinct
from the ‘positive neurological signs’ clinical indicator,
as feedback identified that testing was not routine in
clinical practice; however theoretically this sits within a
neurological examination. It is well established that
small fibre degeneration occurs before large fibres in
entrapment neuropathies [19]. Furthermore, small fibre
nerve testing correlates more accurately with the IASP’s
definition for NP as it tests exclusively sensory fibres.
Small fibre sensory testing is commonly used in experi-
mental research studies investigating NP through means
such as quantitative sensory testing (QST) [37] and skin
biopsy [38]. However as this list of indicators is directed
not only at researchers but a clinical population as well,
the use of a bedside clinical examination remains the most
relevant. Zhu et al. [39] found significant correlations be-
tween clinical sensory tests and QST when evaluating
somatosensory dysfunction in 3 cohorts of patients (carpal
tunnel syndrome, lumbar radicular and non-specific arm
and neck pain). However, not all components of the clin-
ical sensory tests were found to be useful, with variations
in findings between patient cohorts highlighting the need
to consider condition specific parameters. Standardised
qualitative sensory testing (SQST) was found to have low/
moderate sensitivity (62%) and high specificity (95%) when
detecting lumbar lateral stenosis of the L5 nerve root.
However due to indirectness of the evidence, a low level
of evidence supports the use of SQST in diagnosing lum-
bar lateral stenosis of the L5 nerve root [17]. This Delphi
supports the use of this clinical indicator. However further
research into what constitutes an effective battery of clin-
ical tests of the small fibres in identifying NP in low back
related leg pain is needed and importantly what the diag-
nostic utility of these tests are.
Reports of spontaneous pain (i.e. stimulus independ-
ent) and/or paroxysmal pain (i.e. sudden recurrences
and intensification of pain) just achieved consensus
(71%). This indicator is supported by its use in numer-
ous NP screening tools; Neuropathic Pain Questionnaire
(NPQ) [40], LANSS [31], StEP [33] and painDETECT
[32]. Furthermore, the underlying physiology of NP is
commonly associated with ectopic firing of the primary
afferent nerve following peripheral nerve insult. Sites of
ectopic firing develop in response to nerve injury, occur-
ring at multiple sites including; injury site, dorsal root
ganglia [41] and in the surrounding non-injured affer-
ents [42]. Compelling evidence to support spontaneous
pain in clinical presentations of NP in low back related
leg pain is however minimal. Moderate level evidence
supports the use of a cluster of 8 subjective signs, of
which paroxysmal pain is one, when diagnosing lumbo-
sacral nerve root compression, demonstrating moderate/
high sensitivity (72%) and specificity (80%) values. How-
ever, the diagnostic utility of this indicator is yet to be
investigated in isolation [17], and this lack of evidence
was also highlighted by participants in this study. This
Delphi study supports the use of this indicator to in-
crease the index of suspicion of NP in low back related
leg pain however agreement was only just achieved. Fur-
ther research is needed to investigate the diagnostic utility
of this indicator in order for a stronger recommendation
to be made.
The indicator of allodynia and hyperpathia within the
distribution of pain just achieved consensus (74.2%).
Attal et al. [43] found in a study involving participants
with NP disorders, including lumbar radiculopathy, 55%
were found to have brush evoked allodynia. Jensen and
Finnerup [44] suggested that in NP disorders areas of
allodynia and hyperpathia provide a measure of those
structures within the nervous system where signs of
neuronal hyperexcitability are present. A common
theme identified widely amongst participants was that
the indicator is also conducive with nociplastic pain/cen-
tral sensitisation and that evidence surrounding the
presence of allodynia and hyperpathia in identifying NP
in low back related leg pain is limited. These findings
are supported by our systematic review in which allody-
nia and hyperpathia are not featured as an index test in
any of the included studies investigating NP in low back
related leg pain [17]. Allodynia and hyperalgesia/hyper-
pathia are not limited to NP and therefore the use of this
indicator must be considered with other clinical signs
and as a means to increase index of suspicion of NP in
low back related leg pain. This review supports the use
of this indicator in identifying NP in low back related leg
pain, however as agreement was only marginally
achieved this should reflect the index of suspicion when
used.
Study findings compared to Smart et al’s (2010) original
list
From Smart et al’s original list 7 indicators were
retained, 1 additional indicator was added and 7 were
removed. Of the 7 indicators retained, 3 indicators
remained unchanged from the original list; ‘Pain in asso-
ciation with other neurological symptoms (e.g. pins and
needles, numbness, weakness),’ ‘Reports of spontaneous
pain (i.e. stimulus independent) and/or paroxysmal pain
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(i.e. sudden recurrences and intensification of pain)’ and
‘Positive neurological signs (including altered reflexes,
sensation and muscle power in dermatomal/myotomal
or cutaneous nerve distribution).’ Two of the indicators
were modified slightly to specify a low back related leg
pain component to the indicator; ‘Pain variously de-
scribed as burning, electric shock like and/or shooting
into leg’ and ‘History of nerve injury, pathology or mech-
anical compromise at the region of the nerve root/or
other nervous tissue around the lumbar spine that can
refer into the leg.’ Two indicators were worded slightly
differently to improve readability/comprehension follow-
ing participant feedback; ‘Pain described as crawling or
another unpleasant abnormal sensation (as a common
example of dysesthesia)’ and ‘Allodynia and/or hyper-
pathia within the distribution of pain.’ One indicator was
added to this list which was not on Smart et al’s original
list; ‘Loss of function of small fibre nerve testing.’ The
evidence surrounding the above indicators have been
described earlier in the discussion.
Seven indicators were removed from Smart et al’s
original list; ‘pain referred in a dermatomal or cutaneous
distribution,’ ‘Less responsive to simple analgesia/
NSAIDS and/or more responsive to anti-epileptic (e.g.
Neurontin, Lyrica)/anti-depression (e.g. Amitriptyline)
medication,’ ‘Pain of high severity and irritability (i.e.
easily provoked, taking longer to settle),’ ‘Mechanical
pattern to aggravating and easing factors involving
activities/postures associated with movement, loading or
compression of neural tissue,’ ‘Pain/symptom provoca-
tion with mechanical/movement tests (e.g. Active/Pas-
sive, Neurodynamic, i.e. SLR, Brachial plexus tension
test) that move/load/compress neural tissue,’ ‘Pain/
symptom provocation on palpation of relevant neural
tissues’ and ‘Antalgic posturing of the affected limb/body
part.’ The differences between Smart et al’s list and the
list generated from the current Delphi may be reflective
of the difference in phenomena of interest in each study
(NP in low back related leg pain and NP in musculoskel-
etal pain). Furthermore, there is a nine-year time differ-
ence between the two studies and therefore the resultant
lists may be reflective of the evidence available at that
particular time. Finally, the differences between lists
could be attributed to the expert populations in each
study, which were both defined differently.
In addition to the reasons provided for variation be-
tween each list, specific evidence pertaining to each indi-
cator has been highlighted as possible reasons for why
the indicator was removed from the original list. Pain re-
ferred in a dermatomal or cutaneous distribution has
been disputed as an indicator for NP with evidence in
both animal and human studies describing extraterritor-
ial spread of symptoms in response to entrapment neu-
ropathies [19]. Evidence surrounding neurodynamic
testing and nerve palpation in relation to identifying NP
is sparse however it is well established that these tests
have low diagnostic validity and thus may not be a useful
clinical indicator [19]. The removal of the indicator
regarding pharmacotherapy may be consistent with the
lack of evidence supporting the efficacy of any particular
medication in NP, highlighted in a systematic review by
Finnerup et al. [17]. The remaining indicators surround-
ing antalgic postures, mechanical aggravating factors and
high irritability are not described in any of the contem-
porary screening tools or classifications pertaining to NP
and have not been investigated in isolation for their
diagnostic accuracy which may be the reason for their
removal from the list [14].
Strengths and limitations
Strengths of this study include the use of a robust
methodology which adhered to a pre-defined published
protocol [23]. The study is reported in line with the
CREDES recommendations, which is the only reporting
guidance tool available for Delphi studies [45]. Finally,
on completion of this study a list of clinical indicators
was generated (good agreement) and, alongside the find-
ings of our recent systematic review, recommendations
to inform future research have been made.
A limitation to this study was that the expert partici-
pants were largely made up of physiotherapists and
therefore not fully representative of all healthcare profes-
sionals. The study recruited national and international
experts with representatives from research/academia and
clinical practice, however a large proportion of the ex-
pert participants were from the UK and therefore con-
sensus may not be fully representative of internationally
accepted opinion. A further limitation to this study was
the size of the participant sample. When compared to
other Delphi studies related to low back pain the num-
bers in this study were significantly lower [46, 47].
Clinical and research recommendations
A list of 8 clinical indicators has been agreed to identify
possible NP in low back related leg pain. Higher levels of
agreement were demonstrated for 5 of the clinical indi-
cators and therefore it is recommended that the pres-
ence of these indicators should heighten the clinician’s
index of suspicion compared to the other 3 indicators:
 Pain variously described a burning, electric shock
like and/or shooting into leg
 Pain in association with other neurological
symptoms (e.g. pins and needles, numbness,
weakness)
 Pain described as crawling or another unpleasant
abnormal sensation (as a common example of
dysesthesia)
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 History of nerve injury, pathology or mechanical
compromise at the region of the nerve root/or other
nervous tissue around the lumbar spine that can
refer into the leg
 Positive neurological signs (including altered
reflexes, sensation and muscle power in
dermatomal/myotomal or cutaneous nerve
distribution)
Evidence to support the use of these clinical indicators
demonstrates some promise, particularly when consider-
ing pain descriptors and ‘history of nerve injury, pathology
or mechanical compromise.’ However, the diagnostic util-
ity of these indicators individually when identifying NP in
low back related leg pain remains unclear [17]. Therefore,
further research should evaluate the diagnostic accuracy
of each of the 8 clinical indicators generated from this
study, in a high quality, low risk of bias cross-sectional
study. Furthermore, clarity is needed regarding aspects of
the definition of NP in relation to what constitutes a le-
sion/disease of the somatosensory nervous system and
how can this be identified. Importantly, research needs to
establish the prevalence of the 8 criteria among formally
diagnosed patients to give some indication of how often
the criteria might be useful in practice.
This list of clinical indicators is the first of its kind, as it is
the only list of indicators which are specific to identifying
NP in low back related leg pain. The authors do not recom-
mend that this list provides an alternative to other sources
of evidence specific to NP (screening tools, classifications)
but its use may heighten the suspicion of the presence of
NP in low back related leg pain. Further research is needed
before implementation into clinical practise in relation to
measurement properties, such as reliability, validity, feasibil-
ity and acceptability.
The authors of this study support the use of this list of
clinical indicators as a means to increase the index of sus-
picion for the presence of NP in low back related leg pain,
however this should be interpreted alongside clinical
examination findings and clinician experience. Stronger
recommendations regarding this list can be made once
the diagnostic utility of these indicators is investigated.
Conclusion
Good agreement was found for the consensus derived
list of 8 clinical indicators to identify possible NP in low
back related leg pain. Five of the 8 clinical indicators
demonstrated higher levels of agreement amongst ex-
perts and are therefore recommended to heighten the
clinician’s index of suspicion relative to the other 3 indi-
cators. Evidence to support the diagnostic utility of each
of the 8 clinical indicators is limited and therefore a
need for further research in this area is required for
stronger recommendations to be made.
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